Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Biotechnology

Healthcare
$1.86 -1.41%

-$0.02 today

Market cap
$141.41M
Beta
2.08
P/E (TTM)
-25.1
EPS (TTM)
-$0.06
52W Low $1.43High $67.00

Volume 0.07M

Average 0.10M

MENS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Jyong Biotech Ltd. Ordinary SharesNASDAQ: MENS

Weighted Avg Shares (Diluted) · Q4 FY2025 · quarter ended Dec 2025

Weighted avg shares (diluted) grows 103626.1% year over year

Q4 FY2025 weighted avg shares (diluted) of 74.23M shares rose 103626.1% year over year. Over 3 fiscal years it compounded at -1.3% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
74.23M— QoQ
Last fiscal yearDec 2025
73.01M-4.0% YoY
LTMDec 2024
71.57K— YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+103626.1%——
1 year-4.0%——
3-year CAGR-1.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
73.01M USD
Year-over-year change
-4.0%
4-year CAGR
-1.0%

Weighted Avg Shares (Diluted) vs competitors

How MENS compares with its peers on the latest reported figures

  • MENS's LTM Dec 2024 weighted avg shares (diluted) of 71.57K shares is the lowest of the 11 companies compared; the peer median is 92.03M shares.
  • Over three fiscal years its annual growth of -1.3% compares with a peer median of +12.0%.
MENS Competitors Peer median
Weighted Avg Shares (Diluted) for MENS and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026189.27M +2.9%+5.0%
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
CNTACentessa Pharmaceuticals plcLTM Mar 2026139.28M +13.5%+13.3%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +2.0%+11.8%
XENEXenon Pharmaceuticals Inc.LTM Sep 202691.49M +16.1%+9.4%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
CGONCG Oncology, Inc. Common stockLTM Sep 202684.72M +15.3%+5.1%
APGEApogee Therapeutics, Inc.LTM Jun 202666.14M +15.7%+6.2%
CELCCelcuity Inc.LTM Jun 202651.65M +19.9%+50.5%
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 202471.57K —-1.3%
Peer median (excluding MENS) 92.03M+15.5%+12.0%

Competitors are the stored peer set for MENS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue121K122K127K120K100K
Gross Profit(121K)(122K)(127K)(120K)(100K)
Gross Margin—————
Research & Development1.56M1.29M1.07M927K731K
Selling, General & Admin845K1.54M1.73M1.13M1.78M
Operating Expenses2.4M2.83M2.8M2.06M2.51M
Depreciation & Amortization122K123K127K120K100K
EBITDA(3.24M)(5.74M)(3.52M)(1.86M)(2.51M)
EBITDA Margin—————
Operating Income(2.4M)(2.83M)(2.8M)(2.06M)(2.61M)
Operating Margin—————
Interest Income6K5K56K7K610K
Interest Expense835K765K757K1.04M2.54M
Other Income / Expenses(1.79M)(3.8M)(1.6M)(963K)(2.06M)
Income Before Tax(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(4.2M)(6.63M)(4.4M)(3.02M)(4.67M)
Net Margin—————
EPS (Basic)(0.06)(0.09)(0.06)(0.04)(0.06)
EPS (Diluted)(0.06)(0.09)(0.06)(0.04)(0.06)
Weighted Avg Shares76.03M76.03M76.03M76.03M73.01M
Weighted Avg Shares (Diluted)76.03M76.03M76.03M76.03M73.01M

Jyong Biotech Ltd. Ordinary Shares

NASDAQ:MENS

Intrinsic Alpha fair value

Locked

Current Price

$1.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.